Share

July 2020; 7 (4) ArticleOpen Access

COVID-19 and MS disease-modifying therapies

Joseph R. Berger, Rachel Brandstadter, Amit Bar-Or
First published May 15, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000761
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2271

Share

Article Information

vol. 7 no. 4 e761
DOI: 
https://doi.org/10.1212/NXI.0000000000000761
PubMed: 
32414755
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received April 16, 2020
  • Accepted in final form April 26, 2020
  • First Published May 15, 2020.
Copyright & Usage: 
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Joseph R. Berger, MD,
    2. Rachel Brandstadter, MD and
    3. Amit Bar-Or, MD
  1. Joseph R. Berger, MD,
    2. Scientific Advisory Boards:

    1. Dr. Berger serves as a consultant and/or on the PML adjudication committees of Novartis and Takeda/Millennium. He also serves on the Scientific Advisory Board ExcisionBio and Inhibikase. He is chair of the Data Safety Monitoring Board for MAPI.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Dr. Berger has received honoraria from Prime Education, AcademicCME, Arcus Medica, Eisenhower Medical Center, River West Meetings, and the MS Foundation for lectures.

    Editorial Boards:

    1. Dr. Berger serves as an editorial board member of the Journal of Neurovirology, Neurology Reviews and MS and Related Disorders

    Patents:

    1. NONE

    Publishing Royalties:

    1. Portegies P, Berger JR (Editors): HIV/AIDS and the Nervous System. In Vinken PJ, Bruyn G (Editors): Handbook of Clinical Neurology, Volume 85; Elsevier, Amsterdam, 2007.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr. Berger serves as a consultant to Biogen, Celgene, Dr. Reddy, EMD Serono, Genzyme/Sanofi, Merck, Novartis, Roche/Genentech, Morphic, Encycle, Novartis, and Millennium/Takeda.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1) Biogen 2) Genentech

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Rachel Brandstadter, MD and
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Amit Bar-Or, MD
    4. Scientific Advisory Boards:

    1. Receptos-Celgene, Advisor, Scientific Board, 2011 - Sanofi/Genzyme, Advisor, Scientific board, 2017 - Roche/Genentech, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- GSK, Advisor 2012 - 2014 Atara Therapeutics, Advisor, Scientific Board, 2017 - Guthy Jackson Greater Good Foundation, Scientific Advisor, 2008- Immune Tolerance Network - Steering Committee, 2016 -

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Receptos-Celgene, Advisor, Scientific Board, 2011 - Roche/Genentech, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- Sanofi-Genzyme 2015- GSK, Advisor 2012 - 2014

    Editorial Boards:

    1. (1) Neurology, Editorial Board Member, 2008-2015 (2) Clinical and Experimental Neuroimmunology, Editorial Board Member, 2010 -

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Receptos-Celgene, Advisor, Scientific Board, 2011 - Roche/Genentech, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- Sanofi-genzyme - Advisor, 2015 - GSK, Advisor 2012 - 2014 Atara Therapeutics, Advisor, Scientific Board, 2017 -

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis (2) Genzyme-Sanofi (3) Biogen (4) Merck/EMDSerono (5) Roche/Genentech

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Division of Multiple Sclerosis, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  1. Correspondence
    Dr. Berger joseph.berger{at}pennmedicine.upenn.edu
View Full Text

Article usage

Article usage: May 2020 to September 2020

AbstractFullPdfSource
May 2020932049837Highwire
Jun 2020511429491Highwire
Jul 20203062248456Highwire
Aug 2020631992261Highwire
Sep 2020441801226Highwire

Cited By...

Letters: Rapid online correspondence

Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Advertisement